Contact
searchSearch
HMP Global
Login

Treatment

morter and pestle
Treatment
Encompasses all therapeutic interventions tailored to effectively treat cancer.

ONLINE EXCLUSIVES
Building Better Oncology Pathways With Specialty Pharmacy Integration
06/26/2026
Kishen Patel, PharmD
Kishen Patel, PharmD, discusses how integrated specialty pharmacy services are improving adherence, patient engagement, and clinical outcomes in oral oncology care—and why this pharmacist-led model earned Innovation Award recognition at the...
Kishen Patel, PharmD, discusses how integrated specialty pharmacy services are improving adherence, patient engagement, and clinical outcomes in oral oncology care—and why this pharmacist-led model earned Innovation Award recognition at the...
Kishen Patel, PharmD, discusses...
06/26/2026
Journal of Clinical Pathways
Corrigendum
Correction to: NALIRIFOX Compared With FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma: An Overall Survival External Control Arm Study
06/26/2026
Daniel A. King, MD, PhD; Mei Sheng Duh, ScD; Rose Chang, ScD; Louise Yu, MS; Chunyi Xu, MS; Eric M. Maiese, PhD; George Kim, MD
The article published in the March/April issue of the Journal of Clinical Pathways by King et al has been updated to clarify terminology, cohort descriptions, wording, formatting, references, disclosures, and figure/table presentation.
The article published in the March/April issue of the Journal of Clinical Pathways by King et al has been updated to clarify terminology, cohort descriptions, wording, formatting, references, disclosures, and figure/table presentation.
The article published in the...
06/26/2026
Journal of Clinical Pathways
Original Research
NALIRIFOX Compared With FOLFIRINOX for Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma: An Overall Survival External Control Arm Study
04/18/2026
Daniel A. King, MD, PhD; Mei Sheng Duh, ScD; Rose Chang, ScD; Louise Yu, MS; Chunyi Xu, MS; Eric M. Maiese, PhD; George Kim, MD
This study highlights NALIRIFOX as a potentially more effective first-line treatment than FOLFIRINOX for treatment-naive metastatic pancreatic ductal adenocarcinoma.
This study highlights NALIRIFOX as a potentially more effective first-line treatment than FOLFIRINOX for treatment-naive metastatic pancreatic ductal adenocarcinoma.
This study highlights NALIRIFOX...
04/18/2026
Journal of Clinical Pathways
News
Medicare Advantage Linked to Lower Access to High-Quality Cancer Surgery in US
01/19/2026
Grace Taylor, MS, MA
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found...
01/19/2026
Journal of Clinical Pathways
News
McKesson Report Details Key Trends Shaping US Community Oncology Care
01/14/2026
Grace Taylor, MS, MA
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community...
01/14/2026
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Progression-Free Survival in NSCLC: Clinical Utility, Limitations, and Evolving Standards
10/15/2025
Rajat Thawani, MD
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key insights on balancing progression-free and overall survival, the expanding role of biomarker testing, and the promise of multi-omic data integration in reshaping NSCLC treatment.
Rajat Thawani, MD, shares key...
10/15/2025
Journal of Clinical Pathways
Original Research
Standardizing Somatic and Germline Molecular Testing in Prostate Cancer: Care Pathway and EHR Applications
10/15/2025
Mehmet Asim Bilen, MD; Aleksandar Zafirovski, MBA; Robert A. Bailey, MD; Ibrahim Khilfeh, PharmD; Urmi Bapat, MD; Kyra Svoboda, BS; Michael Kramer, MD, MBA
This study presents the development of an evidence-informed care pathway and EHR-integrated tools to standardize tumor and germline testing workflows for patients with metastatic prostate cancer.
This study presents the development of an evidence-informed care pathway and EHR-integrated tools to standardize tumor and germline testing workflows for patients with metastatic prostate cancer.
This study presents the...
10/15/2025
Journal of Clinical Pathways
Original Research
Real-World Outcomes of Next-Generation Sequencing of Progressive Radioactive Iodine Refractory Metastatic Thyroid Cancer and Treatment of These Patients With Redifferentiation Protocol
10/15/2025
Jennifer Wheeley, MS, FNP-C; Nikita Chintapally, MD; Kanchan Kulkarni, MD; Gabriel Yohe, MS; Priya Kundra, MD; Jennifer Rosen, MD; Muhammad M. Shaikh, MD; Meeta Sharma, MD; Jason Wexler, MD; Kenneth D. Burman, MD; Leila Shobab, MD; Irina Veytsman, MD
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted redifferentiation with BRAF and MEK inhibition restored radioactive iodine avidity in the majority of patients with refractory differentiated thyroid cancer, highlighting a promising therapeutic approach.
In this study, targeted...
10/15/2025
Journal of Clinical Pathways
Abstracts
Cost-Effectiveness of BTKis in Medicare Patients With CLL in First-Line and Relapsed/Refractory Settings
08/25/2025
Bhavini Srivastava, MSc; Huimin Li, MA; Pam Martin, PhD; James Gahn, BS; Shaffee Bacchus, PharmD; Erin Franceschini, MS; Kavita Sail, PhD
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price (MFP) was found to be cost-effective compared with acalabrutinib and zanubrutinib at...
Using a semi-Markov model from a US Medicare perspective, ibrutinib priced at the Centers for Medicare & Medicaid Services–negotiated maximum fair price (MFP) was found to be cost-effective compared with acalabrutinib and zanubrutinib at...
Using a semi-Markov model from a...
08/25/2025
Journal of Clinical Pathways
Abstracts
Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer
08/25/2025
Daniel Rubin, PharmD, BCOP; Victoria Handy, PharmD, BCOP; Steven Gilmore, PharmD, BCOP; Stephen Clark, PharmD, BCOP; Aimee Ginsburg, PharmD, BCPS
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within the Clear Value Plus clinical decision support system significantly improved documentation of AKT1, PTEN, and PIK3CA biomarkers and increased the use of precision therapies for hormone receptor–positive,...
Re-prompting providers within...
08/25/2025
Journal of Clinical Pathways
Journal of Clinical Pathways logo

Current Issue

June 2026
Volume 12
Issue 3
Current Issue
Issue Archive

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use